Artemether/Lumefantrine and Vivax Malaria

University of Khartoum

Status and phase: Completed; Phase 3

Conditions: Vivax Malaria

Treatments: Drug: tablets artemether/lumefantrine

Study type: Interventional

Funder types: Other

Identifiers

NCT01625871

vivax

Details and patient eligibility

About

The cure rate of artemether/lumefantrine in the treatment of vivax malaria.

Enrollment: 38 patients

Sex: All

Ages: 5 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with vivax malaria

Exclusion criteria

• severe malaria
• pregnancy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

38 participants in 1 patient group

artemether-lumefantrine

Experimental group

Description:

tablets (containing 20mg artemether and 120 mg lumefantrine) for three days

Treatment:

Drug: tablets artemether/lumefantrine